ALLO — Allogene Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $568.78m
- $124.16m
- $0.10m
- 23
- 14
- 63
- 25
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 114 | 0.156 | 0.095 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 202 | 258 | 294 | 336 | 328 |
Operating Profit | -202 | -258 | -180 | -336 | -328 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -185 | -250 | -182 | -340 | -327 |
Provision for Income Taxes | |||||
Net Income After Taxes | -185 | -250 | -182 | -340 | -327 |
Net Income Before Extraordinary Items | |||||
Net Income | -185 | -250 | -182 | -340 | -327 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -185 | -250 | -182 | -340 | -327 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.8 | -2.08 | -1.34 | -2.38 | -2 |